<DOC>
	<DOCNO>NCT02850874</DOCNO>
	<brief_summary>This single-center , prospective proof-of-concept study design evaluate surgical outcome clinicopathologic result neoadjuvant hyperthermic intraperitoneal chemotherapy ( HIPEC ) conjunction perioperative systemic chemotherapy ( SCT ; neoadjuvant adjuvant ) pancreaticoduodenectomy ( PD ) small cohort patient T1-T3 resectable pancreatic ductal adenocarcinoma ( PDAC ) one high-risk clinical feature . The investigator hypothesize HIPEC administer clinical course reduce postoperative peritoneal disease recurrence . The investigator also expect local recurrence disease reduce . The primary aim study compare 2-year peritoneal disease-free survival patient receive experimental therapy ( neoadjuvant HIPEC + SCT + PD ) historical control receive standard therapy ( SCT + PD ) . Secondary aim determine clinical feasibility outcomes neoadjuvant HIPEC resectable PDAC use patient demographic disease characteristic data .</brief_summary>
	<brief_title>HIPEC Neoadjuvant Treatment Resectable Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Primary diagnosis pancreatic ductal adenocarcinoma ( PDAC ) confine head pancreas classify T1T3 one follow highrisk clinical feature : Carbohydrate antigen ( CA ) 199 great 1,000 U/mL normal bilirubin ; Vascular involvement ; and/or Suspicious regional lymphadenopathy Intention undergo open pancreaticoduodenectomy ( standard Whipple pyloruspreserving pancreaticoduodenectomy ) treatment PDAC Adequate clinical condition undergo preoperative ( neoadjuvant ) hyperthermic intraperitoneal chemotherapy Adequate clinical condition undergo perioperative systemic chemotherapy White blood cell count least 3000/mL Platelet count least 100,000/mL Normal creatinine ( &lt; 2 mg/dL ) creatinine clearance least 50 mL/min Willing able give inform consent Evidence locoregional spread ( carcinomatosis peritoneal surface , mesenteric artery , body/tail pancreas ) distant ( liver , lung , ) metastasis ( histological , CT , MRI confirmation ) Noncurative intent treatment ( â‰¥R2 resection ) Body mass index ( BMI ) &gt; 35 Previous history pancreatic resection tumor body and/or tail pancreas , distal cholangiocarcinoma , duodenal carcinoma , neuroendocrine tumor , cystadenocarcinoma , solid papillary tumor . Unstable uncompensated respiratory cardiac disease Severe hepatic renal dysfunction Bleeding diathesis coagulopathy Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>hyperthermic intraperitoneal chemotherapy</keyword>
	<keyword>perioperative systemic chemotherapy</keyword>
	<keyword>peritoneal disease</keyword>
</DOC>